MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells

Moghbeli, Meysam

doi:10.1186/s13048-021-00882-1

Cited by 38 publications

(17 citation statements)

References 209 publications

(256 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, most patients develop resistance to cisplatin therapy, ultimately leading to treatment failure and tumor progression. Cisplatin resistance depends on multiple factors such as induction of anti-apoptotic signals, drug inactivation, increased DNA repair, increased stemness, and EMT ( 54 ). Unlike 5-FU resistance mechanisms, USP22 increases tumor resistance to cisplatin by enhancing DNA repair capacity.…”

Section: Resistance Mechanism Of Usp22mentioning

confidence: 99%

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

Guo

Zhao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Regulation of ubiquitination is involved in various processes in cancer occurrence and development, including cell cycle arrest, cell proliferation, apoptosis, invasion, metastasis, and immunity. Ubiquitination plays an important role not only at the transcriptional and post-translational levels but also at the protein level. When ubiquitination is in a pathological state, abnormally activated biological processes will not only induce cancer progression but also induce immune evasion. The main function of deubiquitinases (DUBs) is to remove ubiquitin chains from substrates, changing the biological activity of the substrates. It has great potential to improve the prognosis of cancer by targeting DUB to regulate proteome. Ubiquitin-specific peptidase 22 (USP22) belongs to the ubiquitin-specific protease (USP) family of DUBs and has been reported to be related to various physiological and pathological processes. USP22 is abnormally expressed in various malignant tumors such as prostate cancer, lung cancer, liver cancer, and colorectal cancer, which suggests that USP22 may play an important role in tumors. USP22 may stabilize programmed death ligand 1 (PD-L1) by deubiquitination while also regulating T-cell infiltration into tumors. Regulatory T cells (Tregs) are a unique class of immunosuppressive CD4+ T cells that primarily suppress the immune system by expressing the master transcription factor forkhead box protein 3 (FOXP3). USP22 was found to be a positive regulator of stable FOXP3 expression. Treg-specific ablation of USP22 leads to reduced tumor volume in multiple cancer models. This suggests that USP22 may regulate tumor resistance to immunotherapy. In this article, we review and summarize the biological functions of USP22 in multiple signal transduction pathways during tumorigenesis, immune evasion, and drug resistance. Furthermore, we propose a new possibility of combining USP22 with chemotherapeutic, targeted, and immunosuppressive drugs in the treatment of cancer.

show abstract

Section: Resistance Mechanism Of Usp22mentioning

confidence: 99%

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

Guo

Zhao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…They are involved in regulation of cell proliferation, migration, and cell death [ 29 , 30 ]. MiRNAs have also been implicated in the tumor progression and chemo resistance [ 31 , 32 ]. Since, circulating miRNAs are highly stable in urine and blood, they can be used as effective and non-invasive tumor markers [ 33 – 35 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells

et al. 2023

Self Cite

View full text Add to dashboard Cite

Chemotherapy is one of the most common therapeutic methods in advanced and metastatic tumors. Cisplatin (CDDP) is considered as one of the main first-line chemotherapy drugs in solid tumors. However, there is a high rate of CDDP resistance in cancer patients. Multi-drug resistance (MDR) as one of the main therapeutic challenges in cancer patients is associated with various cellular processes such as drug efflux, DNA repair, and autophagy. Autophagy is a cellular mechanism that protects the tumor cells toward the chemotherapeutic drugs. Therefore, autophagy regulatory factors can increase or decrease the chemotherapy response in tumor cells. MicroRNAs (miRNAs) have a pivotal role in regulation of autophagy in normal and tumor cells. Therefore, in the present review, we discussed the role of miRNAs in CDDP response through the regulation of autophagy. It has been reported that miRNAs mainly increased the CDDP sensitivity in tumor cells by inhibition of autophagy. PI3K/AKT signaling pathway and autophagy-related genes (ATGs) were the main targets of miRNAs in the regulation of autophagy-mediated CDDP response in tumor cells. This review can be an effective step to introduce the miRNAs as efficient therapeutic options to increase autophagy-mediated CDDP sensitivity in tumor cells.

show abstract

“…MiRNAs are involved in cell proliferation, differentiation, and apoptosis [ 4 , 5 ]. They may also function as oncogenic or tumor-suppressor, depending on their intracellular roles and expression levels [ 6 , 7 ]. Moreover, aberrant expression of miRNAs has been associated with therapeutic resistance in cancer that suggests these factors as probable efficient therapeutic targets in tumor cells [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular mechanisms of microRNA-216a during tumor progression

et al. 2023

Self Cite

View full text Add to dashboard Cite

MicroRNAs (miRNAs) as the members of non-coding RNAs family are involved in post-transcriptional regulation by translational inhibiting or mRNA degradation. They have a critical role in regulation of cell proliferation and migration. MiRNAs aberrations have been reported in various cancers. Considering the importance of these factors in regulation of cellular processes and their high stability in body fluids, these factors can be suggested as suitable non-invasive markers for the cancer diagnosis. MiR-216a deregulation has been frequently reported in different cancers. Therefore, in the present review we discussed the molecular mechanisms of the miR-216a during tumor progression. It has been reported that miR-216a mainly functioned as a tumor suppressor through the regulation of signaling pathways and transcription factors. This review paves the way to suggest the miR-216a as a probable therapeutic and diagnostic target in cancer patients.

show abstract

MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells

Cited by 38 publications

References 209 publications

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

Immune Evasion and Drug Resistance Mediated by USP22 in Cancer: Novel Targets and Mechanisms

MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells

Molecular mechanisms of microRNA-216a during tumor progression

Contact Info

Product

Resources

About